Does the media favor AMRX or VTRS?

In the previous week, Viatris had 7 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Viatris and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Viatris' score of 0.46 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NBIX or AMRX?

In the previous week, Neurocrine Biosciences had 20 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Neurocrine Biosciences' score of 0.75 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 13 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 28 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 34 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Jazz Pharmaceuticals' score of 0.53 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 10 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or AMRX?

In the previous week, Elanco Animal Health had 25 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 31 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Elanco Animal Health's score of 0.77 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 11 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMRX or CORT?

In the previous week, Corcept Therapeutics had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Corcept Therapeutics' score of 0.85 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Amneal Pharmaceuticals (AMRX) Competitors

$18.14 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$18.02 -0.13 (-0.69%)

As of 05:53 AM Eastern

Compare

AMRX vs. VTRS, NBIX, JAZZ, ELAN, and CORT

Should you buy Amneal Pharmaceuticals stock or one of its competitors? MarketBeat compares Amneal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amneal Pharmaceuticals include Viatris (VTRS), Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), and Corcept Therapeutics (CORT). These companies are all part of the "pharmaceuticals" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Viatris (NASDAQ:VTRS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Amneal Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02
Viatris	$14.30B	1.34	-$3.51B	-$0.36	N/A

Amneal Pharmaceuticals presently has a consensus target price of $17.67, indicating a potential downside of 2.61%. Viatris has a consensus target price of $17.50, indicating a potential upside of 6.51%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

In the previous week, Viatris had 7 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for Viatris and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Viatris' score of 0.46 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals has a net margin of 5.05% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Viatris	-2.79%	20.02%	8.02%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Neurocrine Biosciences has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Neurocrine Biosciences has higher revenue and earnings than Amneal Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$3.37B	4.92	$478.60M	$6.82	23.96
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02

In the previous week, Neurocrine Biosciences had 20 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 26 mentions for Neurocrine Biosciences and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Neurocrine Biosciences' score of 0.75 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	13 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Amneal Pharmaceuticals' net margin of 5.05%. Neurocrine Biosciences' return on equity of 22.43% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Neurocrine Biosciences currently has a consensus target price of $201.50, suggesting a potential upside of 23.31%. Amneal Pharmaceuticals has a consensus target price of $17.67, suggesting a potential downside of 2.61%. Given Neurocrine Biosciences' higher possible upside, analysts clearly believe Neurocrine Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Neurocrine Biosciences beats Amneal Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

Amneal Pharmaceuticals has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02
Jazz Pharmaceuticals	$4.60B	3.62	-$356.15M	$14.50	17.69

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Jazz Pharmaceuticals had 28 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 34 mentions for Jazz Pharmaceuticals and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Jazz Pharmaceuticals' score of 0.53 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	10 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus price target of $17.67, indicating a potential downside of 2.61%. Jazz Pharmaceuticals has a consensus price target of $272.74, indicating a potential upside of 6.31%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Jazz Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Amneal Pharmaceuticals' net margin of 5.05%. Jazz Pharmaceuticals' return on equity of 33.97% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Summary

Jazz Pharmaceuticals beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $29.09, indicating a potential upside of 31.88%. Amneal Pharmaceuticals has a consensus target price of $17.67, indicating a potential downside of 2.61%. Given Elanco Animal Health's higher possible upside, equities analysts clearly believe Elanco Animal Health is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 25 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 31 mentions for Elanco Animal Health and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Elanco Animal Health's score of 0.77 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	11 Very Positive mention(s)	4 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.34	-$232M	-$0.41	N/A
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02

Amneal Pharmaceuticals has a net margin of 5.05% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Summary

Elanco Animal Health beats Amneal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Corcept Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.92	$72.06M	$0.49	37.02
Corcept Therapeutics	$761.41M	15.73	$99.65M	$0.42	263.74

Amneal Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential downside of 2.61%. Corcept Therapeutics has a consensus target price of $119.17, suggesting a potential upside of 7.58%. Given Corcept Therapeutics' higher possible upside, analysts clearly believe Corcept Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Amneal Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Corcept Therapeutics had 13 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 19 mentions for Corcept Therapeutics and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat Corcept Therapeutics' score of 0.85 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corcept Therapeutics has a net margin of 6.52% compared to Amneal Pharmaceuticals' net margin of 5.05%. Corcept Therapeutics' return on equity of 8.26% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Corcept Therapeutics	6.52%	8.26%	6.45%

Summary

Corcept Therapeutics beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.79B	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	37.02	790.97	270.58	25.05
Price / Sales	1.92	970.12	658.42	107.93
Price / Cash	11.62	15.12	28.89	37.44
Price / Book	-78.87	10.29	11.18	6.43
Net Income	$72.06M	$2.78B	$3.45B	$348.10M
7 Day Performance	-3.77%	2.78%	3.39%	2.66%
1 Month Performance	6.64%	-0.63%	-0.71%	-0.85%
1 Year Performance	112.41%	192.52%	77.30%	23.96%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	3.2058 of 5 stars	$18.14 flat	$17.67 -2.6%	+112.4%	$5.79B	$3.02B	37.02	8,500
VTRS Viatris	2.3812 of 5 stars	$17.66 +0.1%	$17.50 -0.9%	+69.4%	$20.56B	$14.30B	N/A	30,000	Trending News Earnings Report Dividend Announcement Analyst Downgrade
NBIX Neurocrine Biosciences	4.8963 of 5 stars	$167.41 +0.7%	$201.50 +20.4%	+30.7%	$16.84B	$3.37B	24.56	2,000	Analyst Downgrade
JAZZ Jazz Pharmaceuticals	3.2082 of 5 stars	$261.10 +3.8%	$263.11 +0.8%	+130.5%	$16.37B	$4.44B	N/A	2,890	Trending News Earnings Report
ELAN Elanco Animal Health	4.3456 of 5 stars	$25.55 -0.7%	$28.73 +12.5%	+32.8%	$12.75B	$4.72B	N/A	9,400	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, NBIX, JAZZ, ELAN, and CORT

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, NBIX, JAZZ, ELAN, and CORT

How does Amneal Pharmaceuticals compare to Viatris?

Which has preferable valuation & earnings, AMRX or VTRS?

Do analysts rate AMRX or VTRS?

Which has more volatility & risk, AMRX or VTRS?

Does the media favor AMRX or VTRS?

Is AMRX or VTRS more profitable?

Do institutionals & insiders hold more shares of AMRX or VTRS?

Summary

How does Amneal Pharmaceuticals compare to Neurocrine Biosciences?

Which has more risk & volatility, NBIX or AMRX?

Which has preferable earnings & valuation, NBIX or AMRX?

Does the media favor NBIX or AMRX?

Is NBIX or AMRX more profitable?

Do institutionals and insiders hold more shares of NBIX or AMRX?

Do analysts recommend NBIX or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Jazz Pharmaceuticals?

Which has better valuation and earnings, AMRX or JAZZ?

Do institutionals & insiders have more ownership in AMRX or JAZZ?

Does the media favor AMRX or JAZZ?

Do analysts prefer AMRX or JAZZ?

Which has more risk and volatility, AMRX or JAZZ?

Is AMRX or JAZZ more profitable?

Summary

How does Amneal Pharmaceuticals compare to Elanco Animal Health?

Which has more risk and volatility, ELAN or AMRX?

Do analysts rate ELAN or AMRX?

Do institutionals and insiders believe in ELAN or AMRX?

Does the media favor ELAN or AMRX?

Which has better earnings and valuation, ELAN or AMRX?

Is ELAN or AMRX more profitable?

Summary

How does Amneal Pharmaceuticals compare to Corcept Therapeutics?

Which has preferable earnings and valuation, AMRX or CORT?

Do analysts recommend AMRX or CORT?

Which has more risk & volatility, AMRX or CORT?

Do institutionals & insiders hold more shares of AMRX or CORT?

Does the media favor AMRX or CORT?

Is AMRX or CORT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools